IPSC250117C7500
- 0.00
- 0.000.00%
Century Therapeutics Newsroom
Century Therapeutics Is Maintained at Overweight by Piper Sandler
Century Therapeutics Analyst Ratings
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $4
Clear Street Launches Healthcare & Biotechnology Equity Research
Shinobi Strengthens Leadership to Propel Scalable Immune-Evasive Cell Therapies to the Clinic
Century Therapeutics Faces Termination of BMS Agreement
Bristol-Myers Squibb Notified Century Therapeutics On Dec 12 To Terminate Collaboration Agreement, Effective March 12, 2025; Co To Evaluate Opportunities In AML And Multiple Myeloma In The Context Of The Ongoing Strategic Review Of Century's...
Express News | Century Therapeutics - to Evaluate Opportunities in Aml and Multiple Myeloma
Express News | Century Therapeutics - Termination Effective March 12, 2025
Express News | Century Therapeutics- Bms Notified Co on Dec 12 to Terminate Collaboration Agreement With Century Therapeutics
Analysts Are Bullish on Top Healthcare Stocks: Keros Therapeutics (KROS), Century Therapeutics (IPSC)
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
Takeda in Deal With Alloy Therapeutics to Develop Cell Therapy Platforms for Cancer
Cellino Hosts Second Annual Personalized RegenMed Forum to Accelerate Progress in Regenerative Medicine
Leerink Partners Maintains Century Therapeutics(IPSC.US) With Buy Rating
Promising Phase 1 Results for CNTY-101 in B-Cell Malignancies Boost Confidence in Century Therapeutics
Century Therapeutics, Inc. Demonstrates Strong Financial Management With No Senior Securities Defaults
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $12
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Cuts Target Price to $5